About: Use of recombinant factor VIII Advate in paediatric patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of recombinant factor VIII Advate in paediatric patients Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Recombinant products represent unambiguous technological progress, and are very likely to increase the safety of haemophilia treatment. It is evidenced by their growing consumption, particularly in paediatric patients, in all developed countries which have recommended recombinant products as the treatment of choice. The higher incidence of the inhibitor reported in some publications has not been fully confirmed till this time, and, in addition, the 3rd generation recombinant products appear to be less immunogenic compared to products of previous generations. The lower volume of the product after dissolution is also advantageous for paediatric use.Our limited experience in the treatment with rFVIII Advate is very good, and we are going to struggle to include the recombinant products among fully reimbursed routine treatment of haemophilia. Recombinant products represent unambiguous technological progress, and are very likely to increase the safety of haemophilia treatment. It is evidenced by their growing consumption, particularly in paediatric patients, in all developed countries which have recommended recombinant products as the treatment of choice. The higher incidence of the inhibitor reported in some publications has not been fully confirmed till this time, and, in addition, the 3rd generation recombinant products appear to be less immunogenic compared to products of previous generations. The lower volume of the product after dissolution is also advantageous for paediatric use.Our limited experience in the treatment with rFVIII Advate is very good, and we are going to struggle to include the recombinant products among fully reimbursed routine treatment of haemophilia. (en)
Title	Use of recombinant factor VIII Advate in paediatric patients Use of recombinant factor VIII Advate in paediatric patients (en)
skos:prefLabel	Use of recombinant factor VIII Advate in paediatric patients Use of recombinant factor VIII Advate in paediatric patients (en)
skos:notation	RIV/00843989:_____/09:00100632!RIV10-MZ0-00843989
http://linked.open...avai/riv/aktivita	Z
http://linked.open...avai/riv/aktivity	Z(MZ000064203), Z(MZ0FNM2005)
http://linked.open...iv/cisloPeriodika	Suppl.1
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Ptoszková, Hana Blažek, Bohumír
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Ostrava
http://linked.open...dnocenehoVysledku	347920
http://linked.open...ai/riv/idVysledku	RIV/00843989:_____/09:00100632
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	recombinant products; haemophilia; factor VIII; Advate (en)
http://linked.open.../riv/klicoveSlovo	Advate haemophilia recombinant products factor VIII
http://linked.open...odStatuVydavatele	DE - Spolková republika Německo
http://linked.open...ontrolniKodProRIV	[8B211C0A3F3C]
http://linked.open...i/riv/nazevZdroje	Hämostaseologie
http://linked.open...in/vavai/riv/obor	FG
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	7 (xsd:int)
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	29
http://linked.open...iv/tvurceVysledku	Pospíšilová, D. Černá, Z. Blažek, Bohumír Zapletal, O. Komrska, V. Pindurová, E. Ptoszková, Hana
http://linked.open...ain/vavai/riv/wos	000272214600014
http://linked.open...n/vavai/riv/zamer	Zdokonalení časné diagnostiky, prevence a léčby těžkých vrozených vývojových vad a chorob geneticky podmíněných či s genetickou dispozicí v prenatální a postnatální fázi vývoje Klinicko-genetická studie poruch prenatálního a postnatálního vývoje k časné prevenci, diagnóze a léčbě těžkých VVV, chorob a nádorů s genetickou dispozicí
issn	0720-9355
number of pages	3 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 100 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software